

# Summary of the Effects of Exercise Therapy in Non-Communicable Diseases: Clinically Relevant Evidence from Meta-Analyses of Randomized Controlled Trials

**Author:** Urho M. Kujala, M.D., Ph.D., ORCID ID 0000-0002-9262-1992

Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland

Correspondence to: Prof Urho M Kujala, MD, PhD, Faculty of Sport and Health Sciences, P.O. Box 35 (LL), FIN-40014 University of Jyväskylä, Finland. Tel. +358 40 805 3567

E-mail: [urho.m.kujala@jyu.fi](mailto:urho.m.kujala@jyu.fi)

Running title: Exercise therapy in chronic diseases

## Abstract

There is strong evidence that exercise therapy leads to better measured and self-reported physical fitness and function in patients with chronic diseases, along with improvements in body composition. The evidence for other health benefits has not been summarized as systematically across different chronic diseases. Given the volume of research that has appeared in the past decade, this review of meta-analyses of randomized controlled trials (RCTs) in patients with specific chronic diseases summarizes the evidence regarding exercise therapy for various outcomes to help practitioners in prescribing exercise therapy for their patients. Meta-analyses published before Jan 1, 2021, based on at least four RCTs, and investigating the effect of exercise therapy on the same outcome among patients with a specific chronic disease were screened. These meta-analyses show that, in addition to improvements in fitness and function, various cardio-metabolic risk factor levels are improved in most of the common cardio-metabolic diseases, pain is reduced in musculoskeletal diseases, mood (depression and anxiety) and health-related quality of life are improved in various disease categories, and disease-specific indicators of disease progression are improved for conditions such as type 2 diabetes, hypertension, coronary heart disease, heart failure, claudication, chronic obstructive pulmonary disease, rheumatoid arthritis, fibromyalgia, depression, anxiety, and schizophrenia. Physicians should consider prescribing exercise to their patients with chronic disease conditions to improve their physical fitness, mood, and health-related quality of life and to slow down the progression of disease. This improves a patient's possibility to enjoy an active and independent life.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Key points

- This study summarizes the data from meta-analyses of randomized controlled trials (RCTs) on the effects of exercise therapy in patients and discusses the clinical relevance of the findings.
- The findings include the following: various cardio-metabolic risk factor levels are improved in most of the common cardio-metabolic diseases, pain is reduced in musculoskeletal diseases, mood (depression and anxiety) and health-related quality of life are improved in various disease categories, and disease-specific indicators of disease progression are improved in conditions such as type 2 diabetes, hypertension, coronary heart disease, heart failure, claudication, chronic obstructive pulmonary disease, fibromyalgia, depression, anxiety, and schizophrenia.
- RCTs usually test the same exercise program for all trial participants. To tailor the exercise therapy intervention in real life, individually based factors, such as disease status, fitness level, personal exercising interests and possibilities, and the infrastructure making different exercise therapy modalities possible in the patient's everyday environment should all be considered.

## **Introduction**

There is strong evidence from randomized controlled trials (RCTs) involving patients with chronic disease that exercise therapy leads to better measured and reported physical fitness and function [1]. In addition, exercise training leads to improvements in body composition, particularly controlling body weight and the reduction of visceral fat [2-5]. Epidemiological research shows an association between high physical activity and low risk of death, but on the basis of meta-analyses of high-quality RCTs, exercise therapy does not statistically significantly reduce all-cause mortality [6-8]. However, there remain many potential health benefits of exercise therapy in patients with chronic diseases that fall between the well-demonstrated effects of exercise on fitness and the inconclusive evidence on reducing all-cause mortality.

Genetic factors, many known and unknown confounding factors, and reverse causality may explain the associations between physical activity levels and documented health benefits in observational population follow-ups [7]. To use the resources of health care, strong evidence of those benefits in both theory and real life is needed. Thus, this review is based on clinical experience and meta-analyses of RCTs to summarize the strongest evidence regarding exercise therapy in the treatment of non-communicable diseases (NCDs) among adults. The outcomes reviewed are cardio-metabolic risk factor levels, pain, mood (depression and anxiety), disease-specific indicators of disease progression, and health-related quality of life (HRQoL). The overall goal is to summarize which benefits are based on strong interventional evidence when tailoring exercise therapy for patients. As large amounts of data have been reported during the past decade, this type of summary is important for health care and exercise sector practitioners and decision makers to know for which purposes exercise therapy should primarily be used and which exercise effects are most justified in being recommended to patients and motivate them to exercise.

## **Methods**

### **Review and search strategy and selection criteria of included meta-analyses**

To best serve readers, this review combines clinical, real-life experience with repeated semi-systematic literature searches. Formally, evidence from meta-analyses with at least 4 randomized controlled trials, a total of at least 150 participants, and investigating the effects of exercise therapy on the same outcome among patients with a specific chronic disease is summarized. For studies to be included in this review, the intervention and the control groups had to be primarily contrasted by physical exercise intervention (exercise therapy) and the participants of the trials had to be primarily adults. The protocol is designed for this purpose and does not exactly match earlier published protocol guidelines; it was conducted by only one author.

Data for this review were identified by various yearly literature searches between 2000 and Jan 1, 2021, complemented by searches of PubMed and the Cochrane Database of Systematic Reviews and references in relevant articles through Jan 1, 2021 in early 2021. The design of this review partly follows the design of previous reviews by the same author focusing on the effects of exercise therapy in patients with chronic diseases [9, 10]. However, in this updated version, the findings are classified according to outcomes instead of diseases to evaluate whether similar results are achieved in patients with different chronic diseases, and follow-up in the literature is extended by 12 years compared to the previous review [10]. Large amounts of new data (and most of the data presented here) have appeared in the past decade (see Supplementary file 1).

The searches and this review systematically cover the following NCDs: metabolic syndrome, diabetes, hypertension, coronary heart disease, heart failure, claudication, stroke, asthma, chronic obstructive pulmonary disease (COPD), osteoarthritis, rheumatoid arthritis, low back pain, neck pain, fibromyalgia, osteoporosis, depression, anxiety, schizophrenia, dementia, Parkinson's disease, multiple sclerosis, cancers, and chronic fatigue syndrome, along with individuals living with human immunodeficiency virus (HIV). For search terms of the latest confirmatory searches, see Supplementary file 1. Obesity alone is not included as a disease in this review. The final searches were limited to full-text availability of items written in English. Results from initial follow-ups, usually including the most comprehensive data from the RCTs included in the meta-analyses, are primarily reported. No criteria as to length of follow-ups were established.

Only results with statistically significant effects of exercise therapy compared to controls are included. Generally, the newest meta-analyses are included; older meta-analyses with the same disease and same outcome are not included if they report the same results as the newer ones. In addition, if there was a positive finding in an earlier meta-analysis that was not confirmed by a later meta-analysis with a larger number of trials or higher-quality studies, the meta-analysis results are not included. Due to the large number of outcome variables, only the most clinically important outcomes (based on the author's view as informed by consulting other specialists and clinical benefits for the patient and/or health care system) are included.

The primary interest was to see whether land-based exercise therapy causing physiological loading to the whole body provides benefits; the focus was not on particular types of training. Very specific training modalities such as training respiratory muscles are not included. However, differences in the effects of different types of exercise, such as aerobic versus strength training are discussed when clinically relevant. So-called mind-body exercises, which combine mental and physical exercises (Pilates, tai chi, yoga, and health qigong, and games) are not included in this review; although they may be effective treatment methods in many chronic diseases, their effects may not be due to physical exercise per se.

Meta-analyses do not always report whether the collected results are based on “intention-to-treat” or “per protocol” results of included RCTs. When the results are based on the analysis of an intention to treat, those results are included in this review.

In clinical work, prescribing exercise to formerly inactive patients is often combined with recommendations regarding other health habits such as diet changes, reducing or eliminating smoking or the use of alcohol, but this review concentrates on the independent effects of exercise therapy. Meta-analyses of studies in which other types of interventions have clearly been added to exercise intervention but do not apply to the control group are not included in this review.

## **Summary of findings on the effects of exercise therapy**

In the findings (see Tables 1-5), only meta-analyses providing statistically significant effects sizes on the effects of exercise therapy on clinically significant outcomes are included.

### **Effects on cardio-metabolic disease risk factors**

As expected, changes in cardio-metabolic risk factor levels have been studied most in patients with metabolic syndrome, type 2 diabetes (T2D), and cardio-vascular diseases; exercise-induced improvements in the risk factors have been documented, according to the meta-analyses (Table 1) [4, 11-22]. The findings also include effects on several measures: improvement in blood lipids; reductions in inflammatory parameters, fasting glucose, glycated hemoglobin (HbA<sub>1c</sub>) percent, and systolic blood pressure; and improvements in flow-mediated dilatation of brachial artery, heart rate variability, and left ventricular ejection fraction (Table 1). In chronic kidney disease, exercise reduces blood pressure levels [21, 22]. Although following the selection criteria of this review these findings have been documented by meta-analyses only in specific diseases (Table 1), many of these trends also apply to other chronic diseases, according to individual RCTs.

Interestingly, a meta-regression analysis of 26 RCTs on exercise training in T2D patients showed that exercise frequency in supervised aerobic training and weekly volume of resistance exercise in supervised combined training are associated with a reduction in HbA<sub>1c</sub> percent [23]. A recent meta-analysis by Pan et al. [24] confirmed that both supervised aerobic and resistance exercises reduced HbA<sub>1c</sub> compared to no exercise, and both also reduced triacylglycerol (triglyceride) levels and increased high-density lipoprotein (HDL) cholesterol levels. So, at least for HbA<sub>1c</sub> levels, resistance training reducing skeletal muscle glucose intolerance appears to be a good training modality apart from aerobic training.

## **Effects on pain**

The beneficial effects of exercise therapy on self-reported pain have been shown in chronic musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, nonspecific chronic low-back pain, neck pain, and fibromyalgia (Table 2) [25-36]. Tanaka et al. [37] reported that non-weight-bearing strengthening exercises are more effective than weight-bearing aerobic exercises on short-term pain relief in osteoarthritis. Byström et al. [38] reported that, in patients with chronic low back pain, motor control exercises appear to be more effective than general exercises, while Wang et al. [39] reported that, in patients with chronic low back pain, core stability exercises appear to be more effective than general exercise with regard to pain reduction. However, differentiating between motor control, core stability, and other exercises is not a simple task.

## **Effects on mood (depression and anxiety)**

Symptoms of depression and/or anxiety are reduced not only among patients with a clinical diagnosis of depression and/or anxiety but also in patients with other diseases, including diabetes, arthritis and other rheumatic diseases, Alzheimer's disease, multiple sclerosis, and renal disease; cancer survivors and HIV-positive individuals also saw a reduction in such symptoms (Table 3) [40-48]. The evidence for the reduction of depression is strongest among breast cancer and lymphoma patients [44]. Herring et al. [49] studied the effect of exercise training on depression among patients with any chronic disease and, on the basis of 144 RCTs, the standardized mean difference (SMD) in the effect size for reduction of depression compared to control groups was 0.30 (95% CI, 0.25-0.36). Similarly, anxiety has been shown to decline among chronically ill patients as a result of exercise training (SMD compared to controls 0.29; 95% CI, 0.23-0.36) [50].

## **Effects on progression of chronic diseases**

Theoretically, to have a real effect on disease progression and complications, a longer period of treatment is usually needed to have an effect on physical fitness or risk factor levels; however, there is a growing amount of data from RCT-based meta-analyses in which the main outcome is related to disease progression (Table 4) [8, 28, 32, 34, 51-67]. There is no single generally accepted criterion for following up on the progression of each chronic disease, but disease-specific clinical indicators such as findings from imaging studies, need for hospitalizations due to progression, or disease-specific scores of disease activity or stage can be used to characterize some aspects of disease severity or progression. The general HRQoL and disease-specific questionnaires that seek to assess disease status have overlapping features and cannot be distinctly categorized.

Table 4 provides a summary of findings concerning disease-specific indicators used as outcomes in the meta-analyses. In T2D patients, improved levels of HbA<sub>1c</sub> percent after exercise therapy reflect improved disease status. In hypertension, reductions in systolic and diastolic blood pressure levels

indicate improvement, while a reduction in the need for hospital admissions is seen with coronary heart disease. In heart failure, improvements are gauged by the Minnesota Living with Heart Failure Questionnaire (MLWHFQ) [68, 69], which is one of the most widely used disease-specific HRQoL questionnaires for patients with heart failure. It provides scores for two dimensions, physical and emotional, and a total score. In heart failure with reduced ejection fraction, exercise therapy helps to improve the ejection fraction. In patients with claudication, improvement in disease status is indicated both by longer pain-free walking distance and the physical summary score from the Short Form 36 (SF-36) health survey [70].

In COPD, improvements in shortness of breath are seen by The Chronic Respiratory Disease Questionnaire, the most commonly used disease-specific measurement tool to assess HRQoL in patients with chronic respiratory disease [71, 72]. In patients with severe COPD, improvements have also been reported on St. George's Respiratory Questionnaire (SGRQ) [73, 74] (Table 4).

The Health Assessment Questionnaire has been developed to measure functional outcomes of patients with arthritis and is a valid self-reported measure of patient functional status over time [75, 76]. It has been widely used in rheumatoid arthritis patients, and studies show that exercise improves this score among such patients. In addition, exercise therapy improves scores on the neck disability index in patients with cervical radiculopathy and on the fibromyalgia impact scale in patients with fibromyalgia (Table 4).

In neurological and psychiatric diseases, exercise therapy improves cognitive outcomes among patients with cognitive impairment, reduces depression in patients with depressive disorders and anxiety in patients with anxiety disorders, and reduces symptoms among patients with schizophrenia (Table 4).

### **Effects on health-related quality of life**

Usually, when exercise therapy trials have documented general well-being or quality-of-life outcomes, some degree of trend towards improvement is seen. Convincing findings of improvement in HRQoL from meta-analyses are available for knee and hip osteoarthritis, rheumatoid arthritis, fibromyalgia, Parkinson's disease, schizophrenia, and chronic kidney disease, along with cancer survivors (Table 5) [25, 27, 28, 35, 36, 43, 46, 77-84]. When reporting on quality of life, possible sub-domains that are improved in the absence of improvement in total scores are not formally reported in this review. It should be noted that sub-domains related to physical function are improved in almost all diseases, leading to less physical disability. Improvements in physical function and mood already appear several weeks to months before better HRQoL. To some extent, quality-of life scores overlap with the disease-specific scores of disease progression, and their use varies in specific trials and with specific diseases. HRQoL may see greater improvement if a patient finds exercise therapy enjoyable.

## Comments

### From evidence to real life

This review shows that exercise therapy has a wide variety of beneficial effects among patients with specific chronic diseases. A systematic review of complications was not a focus of this review, but the meta-analyses of the RCTs did not report an excess of severe complications in exercise groups compared to control groups. However, it should be kept in mind when tailoring exercise therapy interventions for patients that the researchers have considered the main contraindications for exercise in their study inclusion criteria and in the baseline screenings of participants.

This review has not extensively discussed the differences between the effects of different types of training. In many disease conditions, different exercise modalities have rather similar effects on health outcomes, and the key factor in real-life settings may be the patients selecting their preferred type(s) of exercise to achieve long-term therapeutic benefits [85]. However, it should be noted that very specific types of exercise may include some advantages in the treatment of specific diseases, such as dancing in Parkinson's disease [86]. In addition, a combination of types of training may be beneficial, as endurance and strength training and varying intensities of training may be due to their differing to some extent from one another; additional mechanisms may increase effect sizes, such as combining different types of training in the treatment of non-insulin-dependent diabetes [87].

Since long-term adherence is a general problem in exercise therapy, supervised exercise programs often lead to better results than non-supervised programs [24], although the cost-effectiveness of programs with little or no supervision may be higher. In some patient groups and intervention types, supervision of patient groups at the beginning of the intervention is indicated, which may be more cost-effective than individually supervised interventions. Cost-effectiveness was not a focus of this review. There is a limited amount of good research available on the cost-effectiveness of exercise therapy, but there are data supporting the cost-effectiveness of exercise therapy in the treatment of patients with coronary heart disease, chronic heart failure, intermittent claudication [88], and sub-acute or chronic low back pain [89]. In RCTs, all exercise intervention patients usually have an identical, predetermined training program. In real life, this is not an optimally cost-effective way to tailor exercise therapies. When individual parameters such as disease stage, physical fitness, motivational factors, exercise preferences, and the infrastructure available for exercising in the nearby everyday environment are considered, the feasibility of exercise therapy and its cost-effectiveness can most likely be improved. In addition, patients need to be followed and personalized support and supervision need to be increased if patients are unable to respond to low-cost exercise recommendations.

When tailoring exercise therapy and possibly selecting objective physical activity monitoring devices, the differences between absolute exercise intensity and exercise intensity relative to fitness level need to be understood [90]. If the monitoring devices available do not permit individual calibration of



exercise intensities, perceived exercise intensity levels can be used for guidance. The goals of the therapy and optimal exercise mode may differ by disease condition. To recover from an acute musculoskeletal condition, a short but intensive muscle training program may be the best option. When trying to achieve cardio-metabolic benefits, it should be noted that the primary goal is long-term behavioral change with an influence on long-term disease progression, although benefits such as increased fitness levels and reduced depression can be achieved even during a short intervention. In addition, in real-life clinical work, it is important not only to increase the physical activity level but also to correct other health behaviors: diet, smoking, use of alcohol, and so on. Participation in exercise programs such as supervised exercise at a gym often leads to dietary changes as a co-intervention, and these are generally not carefully controlled in most published trials.

### **Methodological considerations and main limitations**

There are some limitations in the studies on which the meta-analyses are based. First, many exercise therapy studies have involved fairly low numbers of participants to document uncommon severe complications and, due to the nature of the intervention, they are less often rigorously blinded or placebo-controlled than pharmacological clinical trials. While randomization and intention-to-treat analyses have been carried out in recent RCTs, there appears to be an ongoing problem with concealment of allocation, as in many meta-analyses the effects are not as strong in the sub-group of studies where concealment of allocation has been properly described. This also explains why effects of exercise therapy on mortality did not reach a high enough standard of evidence to be included in the present study [91, 92]. A common problem in exercise therapy studies is the insufficient documentation and analysis of possible co-interventions, such as changes in medication or diet. Also, improvement in medications both in exercise and control groups may reduce the independent effects of exercise on disease progression. Generalizability may be a further problem, as many RCTs include patients who are not representative of the general population of patients with respect to age, gender, exercise motivation, and coexisting diseases. In RCTs, volunteer patients may be more motivated to follow exercise therapy recommendations than the overall patient population in real life, so interviews on motivational factors are important in clinical practice. The limitations of this review include its having only one author and a novel review process design; however, the author has a long track record of clinical experience in sports and exercise medicine and in conducting traditional systematic reviews.

### **Future challenges and conclusion**

Evidence of many health benefits of exercise therapy for patients with chronic disease has increased substantially over the past decade. Although meta-analyses including at least four RCTs are not available for all diseases and outcomes, there is promising preliminary evidence for the beneficial effects of exercise therapy in some less frequently studied chronic diseases; still, more high-quality studies with longer follow-ups are needed. Recently, new types of meta-analyses have been

increasingly favored to advance science. Network meta-analyses using both direct and indirect comparisons of different types of exercise therapies have provided additional information on the effectiveness of the therapies [93, 94], although this approach includes the limitation that indirect evidence with only a small number of direct pairwise comparisons may lead to biased conclusions. In addition, data are accumulating from individual participant meta-analyses, which may help in tailoring individually optimized exercise therapies in the future.

Physicians play an important role in paying attention to the physical activity habits of their patients, in evaluating their risks related to vigorous exercise, and in motivating patients when prescribing exercise to those with chronic disease. Collaboration with an exercise physiologist, physiotherapist, or similar allied professional will be beneficial when determining correct exercise intensities and in tailoring and supervising training programs. It is a challenge to know and improve the local collaborative infrastructure to support prolonged exercise participation. A good start to improve treatment practice is to document in patients with chronic disease whether physical activity is already part of their lives and to encourage them to increase physical activity when indicated, based on the findings of this review.

## Declarations

**Data Availability** All data are provided in the article and the Supplementary file 1.

**Conflict of Interests** The author declares that he has no conflict of interest.

**Authorship Contributions** All contributions by UMK.

**Funding** There is no external funding.

## References

1. Pasanen T, Tolvanen S, Heinonen A, Kujala UM. Exercise therapy for functional capacity in chronic diseases: an overview of meta-analyses of randomized controlled trials. *Br J Sports Med.* 2017;51:1459–65.
2. Ohkawara K, Tanaka S, Miyachi M, Ishikawa-Takata K, Tabata I. A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials. *Int J Obes (Lond).* 2007;31:1786–97.
3. Leskinen T, Kujala UM. Health-related findings among twin pairs discordant for leisure-time physical activity for 32 years: The TWINACTIVE study synopsis. *Twin Res Hum Genet.* 2015;18:266–72.

4. Wewege MA, Thom JM, Rye KA, Parmenter BJ. Aerobic, resistance or combined training: A systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome. *Atherosclerosis*. 2018;274:162–71.
5. Kim KB, Kim K, Kim C, Kang SJ, Kim HJ, Yoon S, et al. Effects of exercise on the body composition and lipid profile of individuals with obesity: A systematic review and meta-analysis. *J Obes Metab Syndr*. 2019;28:278–94.
6. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane systematic review and meta-analysis. *J Am Coll Cardiol*. 2016;67:1–12.
7. Kujala UM. Is physical activity a cause of longevity? It's not as straightforward as some would believe. A critical analysis. *Br J Sports Med*. 2018;52:914–8.
8. Taylor RS, Long L, Mordi IR, Madsen MT, Davies EJ, Dalal H, et al. Exercise-based rehabilitation for heart failure: Cochrane systematic review, meta-analysis, and trial sequential analysis. *JACC Heart Fail*. 2019;7:691–705.
9. Kujala UM. Evidence for exercise therapy in the treatment of chronic disease based on at least three randomized controlled trials – summary of published systematic reviews. *Scand J Med Sci Sports*. 2004;14:339–45.
10. Kujala UM. Evidence of the effects of exercise therapy in the treatment of chronic disease. *Br J Sports Med*. 2009;43:550–5.
11. Yousefabadi HA, Niyazi A, Alae S, Fathi M, Rahimi GRM. Anti-inflammatory effects of exercise on metabolic syndrome patients: A systematic review and meta-analysis. *Biol Res Nursing*. 2020; e-pub ahead of print.
12. Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti ATN, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305:1790–9.
13. Kelley GA, Kelley KS. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: A meta-analysis of randomized-controlled trials. *Public Health*. 2007;121:643–55.
14. Chen X, Sun X, Wang C, He H. Effects of exercise on inflammatory cytokines in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. *Oxid Med Cell Longev*. 2020; e-pub ahead of print.
15. Lee JH, Lee R, Hwang MH, Hamilton MT, Park Y. The effects of exercise on vascular endothelial function in type 2 diabetes: a systematic review and meta-analysis. *Diabetol Metab Syndr*. 2018;10:15.
16. Nolan RP, Jong P, Barry-Bianchi SM, Tanaka TH, Floras JS. Effects of drug, biobehavioral and exercise therapies on heart rate variability in coronary artery disease: a systematic review. *Eur J Cardiovasc Prev Rehabil*. 2008;15:386–96.
17. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. *Am J Med*. 2004;116:682–92.

18. Kelley GA, Kelley KS, Franklin B. Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: A meta-analysis of randomized controlled trials. *J Cardiopulm Rehabil.* 2006;26:131–9.
19. Zhang H, Chang R. Effects of exercise after percutaneous coronary interventions on cardiac function and cardiovascular adverse events in patients with coronary heart disease: systematic review and meta-analysis. *J Sports Sci Med.* 2019;18:213–22.
20. Brouwer R, Wondergem R, Otten C, Pisters MF. Effect of aerobic training on vascular and metabolic risk factors for recurrent stroke: a meta-analysis. *Disabil Rehabil.* 2019; e-pub ahead of print.
21. Heiwe S, Jacobsen SH. Exercise training for adults with chronic kidney disease. *Cochrane Database Syst Rev.* 2011;(10):CD007566.
22. Zhang L, Wang Y, Xiong L, Luo Y, Huang Z, Yi B. Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis. *BMC Nephrology.* 2019;20:398.
23. Umpierre D, Ribeiro PA, Schaan BD, Ribeiro JP. Volume of supervised exercise training impacts glycaemic control in patients with type 2 diabetes: a systematic review with meta-regression analysis. *Diabetologia.* 2013;56:242–51.
24. Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. *Int J Behav Nutr Phys Act.* 2018;15:72.
25. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. *Cochrane Database Syst Rev.* 2015;(1):CD004376.
26. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. *Cochrane Database Syst Rev.* 2014;(4):CD007912.
27. Goh SL, Persson MSM, Stocks J, Hou Y, Lin J, Hall MC, et al. Efficacy and potential determinants of exercise therapy in knee and hip osteoarthritis: a systematic review and meta-analysis. *Ann Phys Rehabil Med.* 2019;62:356–65.
28. Baillet A, Zeboulon N, Gossec L, Combescurre C, Bodin LA, Juvin R, et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: Meta-analysis of randomized controlled trials. *Arthritis Care Res.* 2010;62:984–92.
29. Hayden JA, van Tulder MW, Malmivaara AV, Koes BW. Exercise therapy for nonspecific low back pain. *Cochrane Database Syst Rev.* 2005;(3):CD000335.
30. Peek AL, Stevens ML. Different forms of exercise for chronic low back pain (PEDro synthesis). *Br J Sports Med.* 2016;50:188.
31. Chen X, Coombes BK, Sjøgaard G, Jun D, O’Leary S, Johnston V. Workplace-based interventions for neck pain in office workers: Systematic review and meta-analysis. *Physical Therapy.* 2018;98:40–62.
32. Liang L, Feng M, Cui X, Zhou S, Yin X, Wang X, et al. The effect of exercise on cervical radiculopathy: A systematic review and meta-analysis. *Medicine (Baltimore).* 2019;98:e17733.

33. Busch AJ, Barber KA, Overend TJ, Peloso PMJ, Schachter CL. Exercise for treating fibromyalgia syndrome. *Cochrane Database Syst Rev.* 2007;(4):CD003786.
34. Sosa-Reina MD, Nunez-Nagy S, Gallego-Izquierdo T, Pecos-Martin D, Monserrat J, Alvarez-Mon M. Effectiveness of therapeutic exercise in fibromyalgia syndrome: A systematic review and meta-analysis of randomized clinical trials. *BioMed Res Int.* 2017;2356346.
35. Bidonde J, Busch AJ, Schachter CL, Overend TJ, Kim SY, Góes SM, et al. Aerobic exercise training for adults with fibromyalgia. *Cochrane Database Syst Rev.* 2017;(6):CD012700.
36. Bidonde J, Busch AJ, Schachter CL, Webber SC, Musselman KE, Overend TJ, et al. Mixed exercise training for adults with fibromyalgia. *Cochrane Database Syst Rev.* 2019;(5):CD013340.
37. Tanaka R, Ozawa J, Kito N, Moriyama H. Efficacy of strengthening or aerobic exercise on pain relief in people with knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. *Clin Rehabil.* 2013;27:1059–71.
38. Byström MG, Rasmussen-Barr E, Grooten WJA. Motor control exercises reduces pain and disability in chronic and recurrent low back pain. A meta-analysis. *Spine.* 2013;38:E350–8.
39. Wang X-Q, Zheng J-J, Yu Z-W, Bi X, Lou S-J, Liu J, et al. A meta-analysis of core stability exercise versus general exercise for chronic low back pain. *PloS One.* 2012;7:e52082.
40. Narita Z, Inagawa T, Stickley A, Sugawara N. Physical activity for diabetes-related depression: A systematic review and meta-analysis. *J Psychiatr Res.* 2019;113:100–7.
41. Kelley GA, Kelley KS. Exercise reduces depressive symptoms in adults with arthritis: Evidential value. *World J Rheumatol.* 2016;6:23-9.
42. Kelley GA, Kelley KS, Callahan LF. Community-deliverable exercise and anxiety in adults with arthritis and other rheumatic diseases: a systematic review with meta-analysis of randomized controlled trials. *BMJ Open.* 2018;8:e019138.
43. Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. *J Neurol.* 2019: e-pub ahead of print.
44. Brown JC, Huedo-Medina TB, Pescatello LS, Ryan SM, Pescatello SM, Moker E, et al. The effect of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. *PLoS One.* 2012;7:e30955.
45. Lahart IM, Metsios GS, Nevil AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. *Cochrane Database Syst Rev.* 2018;(1):CD011292.
46. Singh B, Spence RR, Steele ML, Sandler CX, Peake JM, Hayes SC. A systematic review and meta-analysis of the safety, feasibility, and effect of exercise in women with stage II+ breast cancer. *Arch Phys Med Rehabil.* 2018;99:2621–36.
47. Song Y-Y, Hu R-J, Diao Y-S, Chen L, Jiang X-L. Effects of exercise training on restless legs syndrome, depression, sleep quality and fatigue among hemodialysis patients: A systematic review and meta-analysis. *J Pain Symptom Manage.* 2018;55:1184–95.

48. Heissel A, Zech P, Rapp MA, Schuch FB, Lawrence JB, Kangas M, et al. Effects of exercise on depression and anxiety in persons living with HIV: A meta-analysis. *J Psychosom Res.* 2019;126:109823.
49. Herring MP, Puetz TW, O'Connor PJ, Dishman RK. Effect of exercise training on depressive symptoms among patients with a chronic illness. A systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med.* 2012;172:101–11.
50. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients. *Arch Intern Med.* 2010;170:321–31.
51. Grace A, Chan E, Giallauria F, Graham PL, Smart NA. Clinical outcomes and glycaemic responses to different aerobic exercise training intensities in type II diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol.* 2017;16:37.
52. Delevatti RS, Bracht CG, Lisboa SDC, Costa RR, Marson EC, Netto N, et al. The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis. *Sports Med Open.* 2019;5:22.
53. Cornelissen VA, Fagard RH. Effect of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. *J Hypertens.* 2005;23:251–9.
54. Cao L, Li X, Yan P, Wang X, Li M, Li R, et al. The effectiveness of aerobic exercise for hypertensive population: A systematic review and meta-analysis. *J Clin Hypertens (Greenwich).* 2019;21:868–76.
55. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev.* 2011;(7):CD001800.
56. Lawler PR, Filion KB, Eisenberg MJ. Efficacy of exercise-based cardiac rehabilitation post-myocardial infarction: A systematic review and meta-analysis of randomized controlled trials. *Am Heart J.* 2011;162:571–84.
57. Dallas K, Dinas PC, Chryssanthopoulos C, Dallas G, Maridaki M, Koutsilieris M, et al. The effects of exercise on VO<sub>2</sub>peak, quality of life and hospitalization in heart failure patients: a systematic review with meta-analyses. *Eur J Sport Sci.* 2020; e-pub ahead of print.
58. Tucker WJ, Beaudry RI, Liang Y, Clark AM, Tomczak CR, Nelson MD, et al. Meta-analysis of exercise training on left ventricular ejection fraction in heart failure with reduced ejection fraction: A 10-year update. *Prog Cardiovasc Dis.* 2019;62:163–71.
59. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst Rev.* 2017;(12):CD000990.
60. Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. *J Gen Intern Med.* 2003;18:213–21.
61. Paneroni M, Simonelli C, Vitacca M, Ambrosino N. Aerobic exercise training in very severe chronic obstructive pulmonary disease. A systematic review and meta-analysis. *Am J Phys Med Rehabil.* 2017;96:541–8.

62. Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P. Efficacy of resistance exercises in rheumatoid arthritis: meta-analysis of randomized controlled trials. *Rheumatology*. 2012;51:519–27.
63. Sanders LMJ, Hortobagyi T, la Bastide-van Gemert S, van der Zee EA, van Heuvelen MJG. Dose-response relationship between exercise and cognitive function in older adults with and without cognitive impairment: A systematic review and meta-analysis. *PLoS One*. 2019;14:e0210036.
64. Jia RX, Liang JH, Xu Y, Wang YQ. Effects of physical activity and exercise on the cognitive function of patients with Alzheimer disease: a meta-analysis. *BMC Geriatr*. 2019;19:181.
65. Rimer J, Dwan K, Lawlor DA, Greig CA, McMurdo M, Morley W, et al. Exercise for depression. *Cochrane Database Syst Rev*. 2012;7:CD004366.
66. Aylett E, Small N, Bower I. Exercise in the treatment of clinical anxiety in general practice – a systematic review and meta-analysis. *BMC Health Serv Res*. 2018;18:559.
67. Sabe M, Kaiser S, Sentissi O. Physical exercise for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis. *Gen Hosp Psychiatry*. 2020;62:13–20.
68. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. *Heart Failure*. 1987;3:198–209.
69. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. *Am J Cardiol*. 1993;71:1106–7.
70. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ*. 1992;303:160–4.
71. Singh S, Sodergren S, Hyland M, Williams J, Morgan M. A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. *Respir Med*. 2001;95:71–7.
72. Guyatt G, Berman L, Townsend M, Pugsley S, Chambers L. A measure of quality of life for clinical trials in chronic lung disease. *Thorax* 1987;42:773–8.
73. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. *Resp Med*. 1991;85(suppl B):2531.
74. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. *Am Rev Respir Dis*. 1992;145:1321–7.
75. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum*. 1980;23:137–45.
76. Brown JH, Kazis LE, Spitz PW, Gertman P, Fries JF, Meenan RF. The dimensions of health outcomes: a cross-validated examination of health status measurement. *Am J Public Health*. 1984;74:159–61.
77. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev*. 2019;(1):CD003331.

78. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: A systematic review and meta-analysis. *Mov Disord*. 2008;23:631–40.
79. Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. *Cochrane Database Syst Rev* 2012;(8):CD007566.
80. Chen YJ, Li XX, Ma HK, Zhang X, Wang BW, Guo TT, et al. Exercise training for improving patient-reported outcomes in patients with advanced-stage cancer: a systematic review and meta-analysis. *J Pain Symptom Manage*. 2020;59:734–49.
81. Soares Falcetta F, de Araujo Vianna Träsel H, de Almeida FK, Falcetta MRR, Falavigna M, Rosa DD. Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. *Breast Cancer Res Treat*. 2018;170:455–76.
82. Hong F, Ye W, Kuo CH, Zhang Y, Qian Y, Korivi M. Exercise intervention improves clinical outcomes, but the “time of session” is crucial for better quality of life in breast cancer survivors: a systematic review and meta-analysis. *Cancers (Basel)*. 2019;11:E706.
83. Larun L, Brurberg KG, Osgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. *Cochrane Database Syst Rev*. 2017;(4):CD003200.
84. Pei G, Tang Y, Tan L, Tan J, Ge L, Qin W. Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis. *Int Urol Nephrol*. 2019;51:1787-95.
85. Miller KJ, Goncalves-Bradley DC, Areerob P, Hennessy D, Mesagno C, Grace F. Comparative effectiveness of three types to treat clinical depression in older adults: A systematic review and network meta-analysis of randomized controlled trials. *Ageing Res Rev*. 2020;58:100999.
86. Carapellotti AM, Stevenson R, Doumas M. The efficacy of dance for improving motor impairments, non-motor symptoms, and quality of life in Parkinson's disease: A systematic review and meta-analysis. *PLoS ONE*. 2020;15:e0236820.
87. Savikj M, Zierath JR. Train like an athlete: applying exercise interventions to manage type 2 diabetes. *Diabetologia*. 2020;63:1491–9.
88. Oldridge N, Taylor RS. Cost-effectiveness of exercise therapy in patients with coronary heart disease, chronic heart failure and associated risk factors: A systematic review of economic evaluations of randomized clinical trials. *Eur J Prev Cardiol*. 2020;27:1045-55.
89. Miyamoto GC, Lin CC, Cabral CMN, van Dongen JM, van Tulder MW. Cost-effectiveness of exercise therapy in the treatment of non-specific neck pain and low back pain: a systematic review with meta-analysis. *Br J Sports Med*. 2019;53:172–81.
90. Kujala UM, Pietilä J, Myllymäki T, Mutikainen S, Föhr T, Korhonen I, et al. Physical activity: Absolute intensity versus relative-to-fitness-level volumes. *Med Sci Sports Exerc*. 2017;49:474–81.
91. Posadzki P, Pieper D, Bajpai R, Makaruk H, Könsgen N, Neuhaus AL, et al. Exercise/physical activity and health outcomes: an overview of Cochrane systematic reviews. *BMC Public Health*. 2020;20:1724.



92. Morishita S, Hamaue Y, Fukushima T, Tanaka T, Fu JB, Nakano J. Effect on mortality and recurrence in patients with cancer: a systematic review and meta-analysis. *Integr Cancer Ther.* 2020;19:1534735420917462.
93. Owen PJ, Miller CT, Mundell NL, Verswijveren SJJM, Tagliaferri SD, Brisby H, et al. Which specific modes of exercise training are most effective for treating low back pain? Network meta-analysis. *Brit J Sports Med* 2020;54:1279-1287.
94. de Zoete RM, Armfield NR, McAuley JH, Chen K, Sterling M. Comparative effectiveness of physical exercise interventions for chronic non-specific neck pain: a systematic review with network meta-analysis of 40 randomised controlled trials. *Brit J Sports Med* 2020: e-pub ahead of print.

**Table 1. Effects of exercise therapy on cardio-metabolic risk factors, based on selected meta-analyses of randomized controlled trials in the treatment of patients with specific diseases.**

Study	Disease	Outcome measure	N trials (N participants)	Effect size of exercise compared to controls, pooled statistics (95% CI) <sup>a</sup>
Wewege et al. [4] <sup>b</sup>	Metabolic syndrome	Waist circumference	13 (504)	Mean difference -3.44 cm (-4.81, -2.07)
Wewege et al. [4] <sup>b</sup>	Metabolic syndrome	Fasting blood glucose	11 (471)	Mean difference -0.15 mmol/L (-0.29, -0.02)
Wewege et al. [4] <sup>b</sup>	Metabolic syndrome	HDL cholesterol	9 (427)	Mean difference 0.05 mmol/L (0.01, 0.08)
Wewege et al. [4] <sup>b</sup>	Metabolic syndrome	Triglycerides	11 (471)	Men difference -0.29 mmol/L (-0.43, -0.14)
Yousefabadi et al. [11]	Metabolic syndrome	C-reactive protein (CRP)	29 (1096)	Weighted mean difference -0.52 mg/L (-0.79, -0.25)
Yousefabadi et al. [11]	Metabolic syndrome	Tumor necrosis factor- $\alpha$ (TNF- $\alpha$ )	23 (696)	Weighted mean difference -1.21 pg/mL (-1.77, -0.66)
Wewege et al. [4] <sup>b</sup>	Metabolic syndrome	Diastolic blood pressure	10 (336)	Mean difference -0.59 mmHg (-2.86, -0.32)
Umpierre et al. [12]	Type 2 diabetes	Glycated hemoglobin (HbA <sub>1c</sub> ) percent	23 (1533)	Weighted mean difference -0.67% (-0.84%, -0.49%)
Kelley & Kelley [13] <sup>b</sup>	Type 2 diabetes	LDL cholesterol	4 (156)	Weighted mean difference -6.4 mg/dL (-11.8, -1.1)
Chen et al. [14]	Type 2 diabetes	CRP	18 (996)	Weighted mean difference -0.79 mg/L (-1.26, -0.33)
Chen et al. [14]	Type 2 diabetes	TNF- $\alpha$	10 (350)	Weighted mean difference -2.33 $\mu$ g/mL (-3.39, -1.27)
Lee et al. [15]	Type 2 diabetes	Brachial artery flow mediated dilatation	13 (306)	Hedges' g 0.41 (0.21, 0.62)
Nolan et al. [15]	Coronary heart disease	Heart rate variability	16 (631)	Standardized mean difference 0.36 (0.18, 0.55)
Taylor et al. [17]	Coronary heart disease	Total cholesterol	17 (1903)	Weighted mean difference -0.37 mmol/L (-0.63, -0.11)
Kelley et al. [18] <sup>b</sup>	Cardiovascular disease	HDL cholesterol	6 (637)	Weighted mean difference 3.7 mg/dL (1.2, 6.1)
Taylor et al. [17]	Coronary heart disease	Triglycerides	13 (1442)	Weighted mean difference -0.23 mmol/L (-0.39, -0.07)
Kelley et al. [18] <sup>b</sup>	Cardiovascular disease	Triglycerides	9 (1172)	Weighted mean difference -19.3 mg/dL (-30.1, -8.5)
Zhang & Chang [19]	Coronary heart disease with percutaneous coronary intervention	Left ventricle ejection fraction	5 (735)	Weighted mean difference 2.82% (1.50, 4.14)
Brouwer et al. [20] <sup>b</sup>	Stroke	Systolic blood pressure	6 (377)	Mean difference -3.59 mmHg (-6.14, -1.05)
Brouwer et al. [20] <sup>b</sup>	Stroke	Fasting glucose	4 (184)	Mean difference -0.12 mmol/L (-0.23, -0.02)
Heiwe et al. [21]	Chronic kidney disease	Systolic blood pressure	9 (347)	Mean difference -6.08 mmHg (-10.12, -2.15)
Zang et al. [22]	Non-dialysis chronic kidney disease	Systolic blood pressure	9 (463)	Mean difference -5.61 mmHg (-8.99, -2.23)
Heiwe et al. [21]	Chronic kidney disease	Diastolic blood pressure	11 (419)	Mean difference -2.32 mmHg (-4.05, -0.59)
Zang et al. [22]	Non-dialysis chronic kidney disease	Diastolic blood pressure	8 (399)	Mean difference -2.87 mmHg (-3.65, -2.08)

<sup>a</sup> All estimates reported in this table favor exercise groups; effect sizes are as reported by the authors of original meta-analyses.

<sup>b</sup> The meta-analysis includes only aerobic training trials.

**Table 2. Effects of exercise therapy on pain, based on selected meta-analyses of randomized controlled trials in the treatment of patients with specific diseases.**

Study	Disease	Outcome measure	N trials (N participants)	Effect size of exercise compared to controls, pooled statistics (95% CI) <sup>a</sup>
Fransen et al. [25]	Knee osteoarthritis	Pain	44 (3537)	Standardized mean difference -0.49 (-0.59, -0.39)
Fransen et al. [26]	Hip osteoarthritis	Pain	9 (549)	Standardized mean difference -0.38 (-0.55, -0.20)
Goh et al. [27]	Hip or knee osteoarthritis	Pain	69 (5272)	Standardized mean difference -0.56 (-0.68, -0.44)
Baillet et al. [28] <sup>b</sup>	Rheumatoid arthritis	Pain	6 (261)	Standardized mean difference -0.31 (-0.55, -0.06)
Hayden et al. [29]	Nonspecific chronic (>12 weeks) low back pain	Pain, visual analogue scale (scaled 0 to 100 points)	8 (370)	Weighted mean difference -10.20 points (-19.09, -1.31)
Peek & Stevens [30]	Chronic low back pain	Pain	45 (4462)	Standardized mean difference -0.32 (-0.44, -0.19)
Chen et al. [31]	Neck pain	Pain	5 (605)	Standardized mean difference -0.59 (-0.29, -0.89)
Liang et al. [32]	Cervical radiculopathy	Pain	9 (751)	Standardized mean difference -0.89 (-1.34, -0.44)
Busch et al. [33]	Fibromyalgia	Tender points	6 (349)	Standardized mean difference -0.76 (-1.53, 0.01)
Sosa-Reina et al. [34]	Fibromyalgia	Pain	9 (782)	Standardized mean difference -1.11 (-1.52, -0.71)
Bidonde et al. [35] <sup>b</sup>	Fibromyalgia	Pain	6 (351)	Difference in absolute improvement 11% (4%, 18%)
Bidonde et al. [36]	Fibromyalgia	Pain	15 (832)	Difference in absolute improvement 5% (1%, 9%)

<sup>a</sup> All estimates reported in this table favor exercise groups; effect sizes are as reported by the authors of the original meta-analyses.

<sup>b</sup> The meta-analysis includes only aerobic training trials.

**Table 3. Effects of exercise therapy on mood (depression and anxiety), based on selected meta-analyses of randomized controlled trials in the treatment of patients with specific diseases.**

Study	Disease	Outcome measure	N trials (N participants)	Effect size of exercise compared to controls, pooled statistics (95% CI) <sup>a</sup>
Narita et al. [40]	Diabetes	Depression	13 (962)	Standardized mean difference -0.59 (-0.93, -0.24)
Kelley & Kelley [41]	Arthritis and other rheumatic diseases (osteoarthritis, rheumatoid arthritis, fibromyalgia, and systemic lupus erythematosus)	Depression	29 (2449)	Standardized mean difference -0.48 (-0.64, -0.30)
Kelley et al. [42]	Arthritis and other rheumatic diseases (osteoarthritis, rheumatoid arthritis, and fibromyalgia)	Anxiety	14 (926)	Standardized mean difference -0.40 (-0.65, -0.15)
Dauwan et al. [43]	Alzheimer's disease	Depression	5 (518)	Hedges' g 0.80 (0.12, 1.49)
Dauwan et al. [43]	Multiple sclerosis	Depression	14 (576)	Hedges' g 0.45 (0.12, 0.79)
Brown et al. [44]	Cancer survivors	Depression	40 (2929)	Standardized mean difference -0.13 (-0.26, -0.01)
Lahart et al. [45]	Breast cancer (after adjuvant therapy)	Anxiety	7 (326)	Standardized mean difference -0.57 (-0.95, -0.19)
Singh et al. [46]	Stage II+ breast cancer	Depression	14 (928)	Standardized mean difference -0.66 (-0.80, -0.52)
Singh et al. [46]	Stage II+ breast cancer	Anxiety	14 (1005)	Standardized mean difference -0.77 (-0.91, -0.64)
Song et al. [47]	End-stage renal disease (hemodialysis patients)	Depression	8 (368)	Standardized mean difference -0.95 (-1.18, -0.73)
Heissel et al. [48]	HIV positive	Depression	9 (395)	Standardized mean difference -0.84 (-1.57, -0.11)
Heissel et al. [48]	HIV positive	Anxiety	5 (185)	Standardized mean difference -1.23 (-2.42, -0.04)

<sup>a</sup> All estimates reported in this table favor exercise groups; effect sizes are as reported by the authors of original meta-analyses.

**Table 4. Effects of exercise therapy on disease-specific indicators of disease severity/progression, based on selected meta-analyses of randomized controlled trials in the treatment of patients with specific diseases.**

Study	Disease	Outcome measure	N trials (N participants)	Effect size of exercise compared to controls, pooled statistics (95% CI) <sup>a</sup>
Grace et al. [51] <sup>b</sup>	Type 2 diabetes	Glycated hemoglobin (HbA <sub>1c</sub> ) percent	20 (1347)	Mean difference -0.69% (-1.09, -0.36)
Grace et al. [51] <sup>b</sup>	Type 2 diabetes	Homeostatic model assessment of insulin resistance (HOMA-IR)	7 (442)	Mean difference -1.02 (-1.77, -0.28)
Delevatti et al. [52] <sup>b</sup>	Type 2 diabetes	Glycated hemoglobin (HbA <sub>1c</sub> ) percent	26 (825)	Weighted mean difference -1.04 (-1.39, -0.69)
Cornelissen & Fagard [53] <sup>b</sup>	Hypertension	Systolic blood pressure	30 (492)	Mean net change -6.9 mm Hg (-9.1, -4.6)
Cornelissen & Fagard [53] <sup>b</sup>	Hypertension	Diastolic blood pressure	30 (492)	Mean net change -4.9 mm Hg (-6.5, -3.3)
Cao et al. [54] <sup>b</sup>	Hypertension	Systolic blood pressure	13 (757)	Weighted mean difference -12.26 mmHg (-15.17, -9.34)
Cao et al. [54] <sup>b</sup>	Hypertension	Diastolic blood pressure	13 (755)	Weighted mean difference -6.12 (-7.76, -4.48)
Heran et al. [55]	Coronary heart disease	Hospital admissions (6 to 12 mo follow-up)	4 (463)	Risk ratio -0.69 (-0.93, -0.51)
Lawler et al. [56]	Myocardial infarction	Reinfarction	18 (2550)	Pooled odds ratio 0.54 (0.38, 0.79)
Taylor et al. [8]	Heart failure	MLWHF	17 (1995)	Mean treatment effect -7.1 (-10.5, -3.7)
Dallas et al. [57]	Heart failure	Hospitalizations	26 (4664)	Odds Ratio 0.56 (0.42, 0.75)
Tucker et al. [58]	Heart failure with reduced ejection fraction	Left ventricular ejection fraction	14 (810)	Weighted mean difference 3.79% (2.08, 5.50) for moderate intensity continuous training
Lane et al. [59]	Claudication	Pain-free walking distance	9 (391)	Weighted mean difference 82.1 m (71.7, 92.4)
Lane et al. [59]	Claudication	'Physical summary score' from SF-36 at 6 months	5 (429)	Weighted mean difference 2.15 (1.26, 3.04)
Salman et al. [60]	COPD	Shortness of breath by Chronic Respiratory Disease Questionnaire	12 (723)	Standardized effect size -0.62 (-0.91, -0.26)
Paneroni et al. [61] <sup>b</sup>	Severe COPD	SGRQ	5 (182)	Weighted mean difference -0.04 (-15.3, -0.8)
Baillet et al. [28] <sup>b</sup>	Rheumatoid arthritis	HAQ	9 (771)	Standardized mean difference 0.24 (0.10, 0.38)
Baillet et al. [62] <sup>c</sup>	Rheumatoid arthritis	Joint count	6 (390)	Weighted mean difference -5.36% (95% CI -9.00, -1.72%)
Liang et al. [32]	Cervical radiculopathy	Neck disability index	5 (514)	Standardized mean difference -1.49 (-2.82, -0.17)
Sosa-Reina et al. [34]	Fibromyalgia	Fibromyalgia impact scale	11 (980)	Standardized mean difference -0.67 (-0.89, -0.45)
Sanders et al. [63]	Cognitive impairment	Global cognition	11 (699)	Hedges' d 0.47 (0.19, 0.74)
Jia et al. [64]	Dementia	MMSE score	13 (673)	Standardized mean difference 1.12 (0.66, 1.59)
Rimer et al. [65]	Depression	Depression assessed with different tools	28 (1101)	Standardized mean difference -0.67 (-0.90, -0.43)
Aylett et al. [66]	Anxiety	Anxiety score	6 (194)	Hedges' d -0.41 (-0.70, -0.12)
Sabe et al. [67]	Schizophrenia	PANSS-N	17 (953)	Standardized mean difference -0.24 (-0.42, -0.06)
Sabe et al. [67]	Schizophrenia	PANSS-P	16 (935)	Standardized mean difference -0.18 (-0.34, -0.02)

<sup>a</sup> All estimates reported in this table favor exercise groups; effect sizes are as reported by the authors of original meta-analyses.

<sup>b</sup> The meta-analysis includes only aerobic training trials.

<sup>c</sup> The meta-analysis includes only resistance training trials.

**Abbreviations:** MLWHF = Minnesota Living with Heart Failure questionnaire; SF-36 = Short Form health survey; SGRQ = St. George's Respiratory Questionnaire; HAQ = Health Assessment Questionnaire; MMSE = Mini-Mental State Examination; PANSS-N = Negative symptoms – Positive and Negative Symptoms Scale; PANSS-P = Positive symptoms – Positive and Negative Symptoms Scale.

**Table 5. Effects of exercise therapy on the health-related quality of life benefits, based on selected meta-analyses of randomized controlled trials in the treatment of patients with specific diseases.**

Study	Disease	Outcome measure	N trials (N participants)	Effect size of exercise compared to controls, pooled statistics (95% CI) <sup>a</sup>
Long et al. [77]	Heart failure	Health-related quality of life	26 (3833)	Standardized mean difference 0.60 (0.36, 0.82)
Fransen et al. [25]	Knee osteoarthritis	Quality of life	13 (1073)	Standardized mean difference 0.28 (0.15, 0.40)
Goh et al. [27]	Hip or knee osteoarthritis	Quality of life	33 (2629)	Standardized mean difference 0.21 (0.11, 0.31)
Baillet et al. [28] <sup>b</sup>	Rheumatoid arthritis	Health-related quality of life	5 (586)	Standardized mean difference 0.39 (0.23, 0.56)
Bidonde et al. [35] <sup>b</sup>	Fibromyalgia	Health-related quality of life	5 (372)	Difference in absolute improvement 8% (3%, 13%)
Bidonde et al. [36]	Fibromyalgia	Health-related quality of life	13 (610)	Difference in absolute improvement 7% (3%, 11%)
Dauwan et al. [43]	Schizophrenia	Quality of life	5 (218)	Hedges' g 0.89 (0.22, 1.55)
Goodwin et al. [78]	Parkinson's disease	Health-related quality of life limitations	4 (292)	Standardized mean difference -0.27 (-0.51, -0.04)
Dauwan et al. [43]	Parkinson's disease	Quality of life	19 (1739)	Hedges' g 0.31 (0.08, 0.54)
Dauwan et al. [43]	Multiple sclerosis	Quality of life	25 (1550)	Hedges' g 0.41 (0.24, 0.58)
Mishra et al. [79]	Cancer survivors	Health-related quality of life	11 (826)	Standardized mean difference 0.48 (0.16, 0.81)
Chen et al. [80]	Advanced-stage cancer	Quality of life	8 (564)	Standardized mean difference 0.22 (0.06, 0.38)
Soares Falcetta et al. [81]	Women after treated breast cancer	Quality of life	24 (1961)	Standardized mean difference 0.45 (0.20, 0.69)
Singh et al. [46]	Stage II+ breast cancer	Quality of life	40 (3374)	Standardized mean difference 0.40 (0.33, 0.47)
Hong et al. [82]	Breast cancer survivors	Quality of life	18 (1205)	Standardized mean difference 0.35 (0.15, 0.54)
Larun et al. [83]	Chronic fatigue syndrome	Self-perceived (positive) change in overall health	4 (489)	Risk Ratio 1.83 (1.39, 2.40)
Pei et al. [84] <sup>b</sup>	Chronic kidney disease	Quality of life	7 (562)	Standardized mean difference 8.90 (2.48, 15.32)

<sup>a</sup> All estimates reported in this table favor exercise groups; effect sizes are as reported by the authors of original meta-analyses.

<sup>b</sup> The meta-analysis includes only aerobic training trials.